World News

The EC signed the framework agreement after a request from six participating countries, including Austria, Denmark, Ireland, Luxembourg, Norway, and Portugal.

Under the agreement, Novo Nordisk will internally assess Vivani’s investigational NPM-139 implant, which utilizes the company’s proprietary NanoPortal technology to deliver semaglutide continuously over extended periods through a miniature subdermal device.

Under the agreement, Everest Medicines will receive US$112.5 million upfront from Travere Therapeutics and could earn up to US$1.03 billion more in milestone payments if certain clinical, regulatory, and commercial goals are met across five indications.

The new collaboration centres on CSPC’s small interfering RNA (siRNA) drug discovery platform and its proprietary delivery technology, which is designed to transport therapies beyond the liver.

Following the sale, Clarivate will concentrate on its Academia & Government (A&G) and Intellectual Property (IP) divisions.

The financing round was co-led by M Ventures, the venture capital arm of Merck KGaA, and GordonMD Global Investments.

Astex will also qualify for development, regulatory, and commercial milestone payments exceeding US$465 million, totaling US$490 million with the upfront payment included.

As part of the transaction, Besins Healthcare will take ownership of UniD Manufacturing’s production facility in Seraing, Belgium.

Founded in 2019 as a spinout from Imperial College London and the Francis Crick Institute, Myricx has attracted strong investor backing and has emerged as one of the UK’s leading oncology biotechnology companies.

Under the definitive agreement, which both companies’ boards unanimously approved, Vertex will pay US$85.00 in cash for each outstanding Crinetics share.